Angion Biomedica and Sinovant Sciences Enter into Collaboration and License Agreement to Develop BB3 in Greater China (PDF)
Angion Biomedica expands staff with new Director of Chemistry and Director of Clinical Operations (PDF)
Since 1998 Angion has been developing treatments for major organ diseases.
One in 10 American adults, more than 20 million, has some level of chronic kidney disease.
Angion is testing new treatments to reduce or prevent kidney injury.